Efficacy and Safety of Polyherbal Formulation in Low Sperm Count Participants: A Randomized, Multicenter,...

Male infertility, particularly oligospermia, is characterized by reduced sperm count. It remains a significant clinical concern due to its multifactorial origin and limited therapeutic options. The present study investigates the efficacy and safety of "SHL 1066," a standardized polyherbal formulation, in enhancing semen quality and improving sexual health outcomes in men with low sperm counts.

In a 90-day, multicenter, randomized, double-blinded, placebo-controlled trial, 60 male participants were randomly assigned to receive either "SHL 1066" or a placebo using a computer-generated randomization protocol. Assessments of sperm count, motility, serum total testosterone, and sexual health parameters (erectile function, intercourse satisfaction, and overall satisfaction) were conducted at baseline and study completion.

After 90 days, "SHL 1066" significantly increased sperm count by 72.5% and motility by 14.4%, compared to 8.6% and 6.3%, respectively, in the placebo group. Serum total testosterone levels rose by 23.3%. Sexual health outcomes improved markedly, with erectile function enhanced by 45.5%, intercourse satisfaction by 52.8%, and overall satisfaction by 54%, substantially surpassing placebo outcomes.

"SHL 1066" demonstrated safety, tolerability, and significant efficacy in improving sperm count, motility, testosterone levels, and sexual health compared to placebo. These results position "SHL 1066" as a promising therapeutic option for managing male infertility by enhancing semen quality and sexual function.